Aging w/ Metformin, Rapamycin & More: Longevity Researcher Tells All

Rapamycin Trials

The exploration of Rapamycin's potential to extend lifespan is gaining momentum through significant trials, including the Dog Aging Project. Matt Kaeberlein explains that this large-scale study involves 500 dogs to assess Rapamycin's impact on lifespan and various health measures like cardiac and cognitive function 1. The study aims to determine if Rapamycin can delay aging-related declines and diseases. Participants can nominate their dogs for the project, which involves extensive data collection, including genetic mapping and environmental factors 2.

The primary goal of that study is to answer the question, does rapamycin extend lifespan in middle-aged dogs?

--- Matt Kaeberlein

This research could pave the way for understanding Rapamycin's effects on aging in humans.

   

Metformin and Lifespan

Metformin's role in extending lifespan is a topic of interest, especially when combined with Rapamycin. Matt Kaeberlein notes that while Metformin alone showed no lifespan extension in mice, its combination with Rapamycin did, though the results are not definitive due to study design limitations 3. Human data suggests Metformin benefits diabetic patients by reducing rates of dementia, cancer, and heart disease. However, for non-diabetics, the benefits are less clear, and Metformin might even reduce exercise benefits 4.

People with diabetes who take metformin live longer than people with diabetes who don't take metformin.

--- Matt Kaeberlein

This highlights the complexity of Metformin's effects on aging and healthspan.